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Abstract
Background: Immunoglobulin A (IgA) antibodies to tissue transglutaminase (tTG) are the serologic test of choice
for diagnosing celiac disease (CD). Our aim was to determine if elevated IgA anti-tTG were associated with
increased mortality risk.
Methods: Stored serum samples of National Health and Nutrition Examination Survey (NHANES) III (1988–1992)
were available for 6032 individuals aged 50 years old or above, which were screened for IgA anti-tTG, and if
positive, for IgA endomysial antibodies. Mortality was determined from the National Death Index records through
2006. Hazard ratios were calculated through Cox proportional hazards regression.
Results: From a total of 6032, 85 participants tested positive for IgA anti-tTG (1.4 %) and 5947 tested negative. After a
median follow-up of 13 years, IgA anti-tTG positive participants were at increased risk of death in both crude (HR = 1.68;
95 % CI = 1.30–2.18) and adjusted analyses (adjusted hazard ratio = 1.43; 95 % CI = 1.10–1.85) as compared to IgA anti-tTG
negative participants. The excess mortality was restricted to IgA anti-tTG positive males (adjusted hazard ratio = 1.69 (95 %
CI = 1.26–2.29), as opposed to a hazard ratio of 0.96 (95 % CI = 0.57–1.62) among IgA anti-tTG positive females. Although
the most common cause of death in IgA anti-tTG positive participants was cardiovascular disease (36 %), the increased
hazard ratio was only observed in respiratory cause of death as compared to IgA anti-tTG negative participants (adjusted
hazard ratio = 5.11; 2.76–9.46).
Conclusion: Men aged 50 years old or above participants of NHANES III with elevated IgA anti-tTG antibodies had
increased mortality risk. Elevated IgA anti-tTG antibodies could be a nonspecific marker of serious disease in older men.
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Background
Celiac disease (CD) affects almost 1 % of the American
population yet most cases remain undiagnosed (~80 % of
cases) and the diagnosis is often delayed after patients first
present with typical symptoms [1, 2]. Among current
available serologic tests for CD, Immunoglobulin A (IgA)
antibodies to tissue transglutaminase (tTG) are the sero-
logic test of choice for diagnosing CD [3]. The sensitivity
and specificity of IgA anti-tTG antibodies for CD are
>95 % each [4]. However, diagnostic performance of IgA
anti-tTG antibody tests varies among laboratories due to
lack of standardization of the anti-tTG assay [5]. More-
over, these antibodies can be found in patients without
CD but having other conditions such as chronic liver dis-
ease, heart failure, and autoimmune disorders [6, 7]. Thus,
the presence of IgA anti-tTG antibodies is not exclusive
for CD especially in the context of negative endomysial
antibodies (EMA), the most specific marker for CD [8].
Several population-based studies have shown an asso-
ciation of increased mortality risk in patients with CD
[9–12], but other studies have not [13–15]. Moreover,
studies on the mortality associated with undiagnosed
CD, which was detected by IgA tTG antibodies and/or
EMA positivity, have reported more contradictory
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findings [13, 14, 16–18]. Although, based on the IgA
tTG assays, a European study showed excess mortality
risk particularly due to cancer among individuals with
elevated IgA anti-tTG antibodies over 10 years’ follow-
up period [18], no such study has been performed in a
nationwide sample of the United States with systematical
approaches.
Our main aim was to determine whether elevated IgA
anti-tTG antibodies were associated with higher mortal-
ity risk in a representative sample of the United States
population aged 50 years or older.
Methods
Subjects
The National Health and Nutrition Survey (NHANES) is
conducted by the National Center for Health Statistics
of the Center for Disease Control and Prevention. It col-
lates nationally representative data on the health and nu-
tritional status of the non-institutionalized, civilian
population of the United States. It utilizes a complex,
stratified, and multistage probability sampling design
and collects information from participants using stan-
dardized household interviews, physical examinations,
and testing of biologic samples. More detailed informa-
tion on the survey design for the NHANES, including
approval from the institutional review board for data
collection and analysis, is available from the survey
documentation [1, 19]. For our study, the NHANES III
(1988–1994) database and samples were used.
Laboratory methods to detect CD
Stored serum samples of participants aged 50 years or
above from NHANES III were shipped to the Celiac Dis-
ease Research Laboratory at Mayo Clinic, Rochester,
MN, USA, which performed serological testing using la-
boratory techniques that have been described previously
[1]. Briefly, serum samples were tested for IgA anti-tTG
antibodies using an enzyme-linked immunosorbent assay
for the semiquantitative detection of IgA antibodies to
tTG (CD autoantigen) in human serum using human re-
combinant antigen (Inova; San Diego, CA). Test results
were considered negative if <4.0 U/mL; weakly positive
if 4–10 U/mL; and positive if >10 U/mL. Serum samples
with abnormal IgA-tTG antibodies results (titers ≥4.0 U/
mL) were tested for IgA-EMA by indirect immunofluor-
escence using the reticulin component of the endomy-
sium of the smooth muscle in monkey esophagus tissue
(Inova; San Diego, CA). The result was considered posi-
tive if fluorescence was seen at a dilution of ≥1:5 as pre-
viously reported by our group and many others.
Definition of case and referent subjects
For analytic purposes, participants with abnormal IgA anti-
tTG antibodies were considered cases and participants with
normal IgA anti-tTG antibodies were considered referent
(no exposed) subjects.
Follow-up procedures and ascertainment of death
We used the National Center for Health Statistics up-
dated mortality linkage of the Third National Health and
Nutrition Examination Survey (NHANES III) to death
certificate data found in the National Death Index. The
updated NHANES III Linked Mortality File provides
mortality follow-up data from the date of NHANES III
survey participation (1988–1994) through December 31,
2006. Mortality ascertainment is based upon the results
from a probabilistic match between NHANES III and
National Death Index death certificate records [20].
Statistical analysis
For the univariate analysis we compared proportions
using the Chi-square test, and medians using the Mann-
Whitney U-test. Hazard ratios (HRs) were calculated
through Cox regression. We performed crude analyses,
as well as analyses adjusted for age (continuous variable),
sex, ever-smoking (yes = defined as having smoked >100
cigarettes (5 packs) during lifetime), and race (non-His-
panic white, non-Hispanic black, Hispanic, and other).
The proportional hazards assumption was not violated
as shown by log-minus-log curves. Still, given the differ-
ent HR especially in the first year of follow-up vs. later
we calculated HRs for death according to follow-up
(<1 years, 1- < 5 years; and ≥5 years). We also calculated
stratified analyses according to sex, age at testing (50–
59, 60–69, 70–79, and 80+ years) as well as according to
race.
Follow-up began on the date of IgA anti-tTG antibody
testing and ended with death or end of study period (Dec
31, 2006) whichever occurred first. We calculated absolute
mortality rates according to number of deaths per 1000
person-years. To ensure comparability between IgA anti-
tTG + and IgA anti-tTG - groups we estimated an age- and
sex-standardized mortality in IgA anti-tTG - controls as
the mortality rate in IgA anti-tTG + individuals divided by
the adjusted HR for death. Excess mortality was the differ-
ence in mortality between IgA positive individuals and IgA
anti-tTG negative individuals per 1000 person-years. We
used SPSS 20.0 and JMP for all analyses. P-values were
two-sided and considered statistically significant if <0.05.
Results
Baseline characteristics
Out of 6557 NHANES III participants, a subset of 6034
were tested for IgA-tTG antibodies. Of these, NHANES
categorized two individuals as ineligible for further ana-
lyses due to missing information on vital status. All fur-
ther data refer to the remaining 6032 individuals out of
whom, 85 tested positive for IgA anti-tTG antibody
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(1.4 %; 95 % CI: 1.1–1.7 %), out of which 7 individuals
also tested positive for endomysial antibodies (EMA).
Among 85 positive tTG individuals, 87 % (74/85) were
weakly positive to IgA anti-tTG. Two thirds of the IgA
anti-tTG antibody positive individuals were males (54/
85; 64 %) compared with only 47 % (2793/5947) of IgA
anti-TTG negative individuals (the latter hereby called
referent individuals). The follow-up was significantly
shorter in IgA-tTG antibody positive individuals than in
referent individuals, potentially due to a higher rate of
death among IgA anti-tTG antibody positive individuals.
Table 1 shows the demographic characteristics of study
participants according to the status of IgA anti-tTG
antibody.
Mortality
During follow-up, 58 IgA anti-tTG antibody positive and
2996 referent individuals died (68 vs. 50 %, respectively).
The median age at death was 72 years among IgA anti-
tTG antibody positive individuals vs. 74 years among
referent individuals. Figure 1a shows the survival curves of
IgA anti-tTG antibody positive individuals and referent
individuals, which suggested better survival in referent in-
dividuals (p < 0.001). However, when gender effects were
evaluated, IgA anti-tTG antibody positive individuals had
significantly poor survival only in men (p < 0.001) not in
women (p = 0.8), compared to referent individuals (Fig. 1b
and c, respectively). Of the deceased individuals with avail-
able data on risk factors (n = 3016), 17.2 % of IgA anti-
tTG positive individuals (referent: 11.5 %) had diabetes,
and 8.6 % (referent: 12.5 %) had hypertension. IgA anti-
tTG antibody positive individuals were at increased risk of
death in both crude (HR = 1.68; 95 % CI = 1.30–2.18) and
adjusted analyses (adjusted for age, sex, smoking, and race,
HR = 1.43; 95 % CI = 1.10–1.85) (Table 2). The risk in-
crease was especially high in the first year after testing
(HR = 3.52; 95 % CI = 1.72–7.20), and after the first year of
follow-up there was only a borderline excess mortality
(HR = 1.30; 95 % CI = 0.98–1.72).






Age in years ; median (range) 69 (50–90) 67 (50–90) 0.139
Follow-up in years; median (range) 11 (0–18) 13 (0–18) 0.001
Male (%) 54 (64) 2793 (47) 0.002
Ever smokera (%) 51 (60) 3211 (54) 0.270
Race/ethnicity (%) 0.589
Non-Hispanic White 41 (48) 3298 (55)
Non-Hispanic Black 21 (25) 1209 (20)
Mexican-American 19 (22) 1216 (20)
Other 4 (5) 224 (4)
tTGA tissue transglutaminase antibody
aSmoked at least 100 cigarettes (5 packs) during lifetime
Fig. 1 Unadjusted Kaplan-Meier survival curves for all-cause mortality by IgA anti-tTG antibodies status in the National Health and Nutrition Examination
Survey (NHANES) III from 1988 to 2006. Overall survival for all subjects (a), males (b), and females (c) with elevated IgA anti-tTG antibodies vs. IgA anti-tTG
negative individuals
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The excess mortality was restricted to IgA anti-tTG anti-
body positive males where the HR for death was 1.69, as
opposed to 0.96 in females. This difference was statistically
significant (p for interaction between IgA anti-tTG status
and sex was 0.04). In contrast, mortality HRs did not differ
by age at IgA anti-tTG antibody testing (p for interaction =
0.97) or by race (p for interaction = 0.21) (Table 3).
Table 4 shows the number of total and cause-
specific deaths in IgA anti-tTG positive individuals.
The most common cause of death in IgA anti-tTG
positive individuals was cardiovascular disease (36 %),
however the relative risk of cardiovascular death was
not statistically significant (HR = 1.10), compared to
IgA anti-tTG negative individuals. While only 6 % of
referent individuals died from respiratory disease, the
corresponding fraction was 19 % in IgA anti-tTG anti-
body positive individuals with a relative risk of more
than 5 (HR = 5.11, 95 % CI = 2.76–9.46). However, the
median of IgA anti-tTG antibody titers (4.91, inter-
quartile range = 4.38–6.69) in people who died from
respiratory cause was similar to that of other groups
(5.38, interquartile range = 4.40–6.66) (p = 0.5) among
IgA anti-tTG positive individuals.
Discussion
By testing for IgA anti-tTG antibody stored sera drawn
from a nationally representative sample of individuals
aged 50 or more, we were able to estimate mortality risk
over time associated with elevated IgA anti-tTG anti-
body as compared to no exposed individuals in the
United States population. This study yielded three major
findings. First, the presence of elevated IgA anti-tTG
antibodies was associated with an increased mortality
risk, especially in respiratory cause of death. This finding
is consistent with a prior report from the KORA/MON-
ICA Augsburg cohort study [18]. Second, mortality risk
was limited to men. Third, excess mortality risk is un-
likely to be related to undiagnosed CD as just a minority
had double positive serology (IgA anti-tTG positive and
IgA EMA). We can speculate that elevated IgA anti-tTG
antibodies could be a marker of serious disease in older
men such as chronic pulmonary diseases.
Some studies showed an increased risk of mortality in
undiagnosed CD patients compared to controls [10, 17].
Especially, Metzger et al. [18] showed that individuals
with elevated IgA anti-tTG antibodies present with an
excess of all-cause mortality, particularly due to cancer.
In addition, we found mortality risk was significantly
higher the year after testing for IgA anti-tTG antibodies.
Thus, it is conceivable that presence of IgA anti-tTG
antibodies is associated with serious disease. This is in
contrast with decades needed to demonstrate excess
mortality in subjects with undiagnosed CD (defined by
double positive serology including both IgA anti-tTG
antibodies and IgA EMA) [17]. Although excess of
















All 58 2996 1.43; 1.10–1.85 0.007 74 22
Year <1 8 134 3.52; 1.72–7.20 0.001 100 72
1–4.99 19 778 1.58; 1.00–2.49 0.051 70 26
5+ 31 2084 1.18; 0.83–1.69 0.354 71 11
Reference is general population comparator cohort
tTGA tissue transglutaminase antibody, PYAR Person-years at risk
aAll hazard ratios (HRs) were adjusted for sex, race, age, and ever smoking. See
text for additional explanation
Table 3 Mortality in IgA anti-tTG positive individuals (subgroup analyses)
Subgroup tTGA+ Deaths tTGA- Deaths Adjusted HR; 95 % CI P value Absolute risk/1000 PYAR Excess risk/1000 PYAR
Sex
Males 44 1535 1.69; 1.26–2.29 0.001 96 39
Females 14 1461 0.96; 0.57–1.62 0.881 42 −2
Age
50–59 years 3 272 1.91; 0.61–6.02 0.267 21 10
60–69 years 20 766 1.58; 1.01–2.47 0.044 54 20
70–79 years 22 940 1.49; 0.97–2.27 0.068 103 34
80+ years 13 1018 1.41; 0.81–2.47 0.222 217 63
Race
Non-Hispanic White 29 1794 1.58; 1.09–2.28 0.015 77 28
Non-Hispanic Black 13 603 1.25; 0.72–2.17 0.424 68 14
Mexican-American 13 532 1.23; 0.71–2.15 0.461 68 13
Other 3 67 4.75; 1.45–15.55 0.010 97 76
Reference is general population comparator cohort
tTGA tissue transglutaminase antibody, PYAR Person-years at risk
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overall and respiratory mortality have been demon-
strated in CD [10], it is unlikely that undiagnosed CD
fully explain our findings as just a minority (8 %) of IgA
anti-tTG antibody subjects had double positive serology.
We lacked data on small intestinal histopathology and
biopsies were not used to confirm (or rule out) the pres-
ence of CD in our study population.
We observed an increased risk of respiratory deaths
among those with elevated IgA anti-tTG antibodies. This
findings is similar to a previous study from Sweden [10]
that reported an excess respiratory mortality in children
with latent CD (HR = 2.83; 95 % CI = 1.41–5.67), who had
normal mucosal with positive CD serology. Furthermore,
older reports also showed the association of lung disease
and CD [21, 22]. Robinsons et al. [21] showed that the
higher occurrence of CD in patients with farmer’s lung,
and Axmacher et al. [22] also described an increased oc-
currence of CD in Farmers’ lung. Interestingly, the majority
of cases (about three fourths) were men in these studies.
Our study also showed poor survival in IgA anti-tTG anti-
body positive individuals, especially in men. This finding
suggested that there is a possible association between ele-
vated IgA anti-tTG antibody and respiratory disease, but
the role of undiagnosed CD to explain excess respiratory
disease mortality remains unclear. Moreover, we did not
find any association between higher titers of tTG-IgA and
respiratory cause of death. Our study also showed no sta-
tistically significant increased risk of cardiovascular death
or malignancy related death in IgA anti-tTG antibodies in-
dividuals. In contrast, Metzger et al. [18] reported an in-
creased hazard ratio of cancer mortality (HR = 3.62) for
individuals with an elevated IgA anti-tTG concentration
relative to those with a lower concentration. However,
based on a small number of cancer mortality cases, their
results were inconclusive.
Our study was limited by several factors. Mortality
data was obtained through the National Death Index
and the cause of death reported on death certificates
may suffer from inaccuracies or misclassification. Also,
we note a small sample size in subjects with IgA anti-
tTG positive and EMA (n = 7) to provide robust esti-
mates for mortality of CD autoimmunity. However,
NHANES is the unique database that allows for an un-
biased study of the sero-epidemiology related to CD in
the US civilian population, since NHANES III is a
population-based survey, representative of the US popu-
lation. Another strength is quite a long follow-up period
for estimating mortality rates in the IgA anti-tTG posi-
tive subgroup. Moreover, this study applied a highly sen-
sitive and specific serologic test to a relatively large
number of subjects from the general US population.
Testing was performed by the same laboratory techni-
cians with advanced training in CD using the same
methods and reagents, thus limiting biases due to
personnel or differences due to specific reagents.
Conclusions
In conclusion, men aged 50 years old or above partici-
pants of NHANES III with elevated IgA anti-tTG anti-
bodies had increased mortality risk. Mortality risk is not
related to undiagnosed CD as just a minority had double
positive serology (IgA anti-tTG positive and IgA EMA).
Elevated IgA anti-tTG antibodies could be a nonspecific
marker of serious disease in older men.
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